CD274 and cancer: Overall, they not only uncovered a key role for exosomal PD‐L1 in enabling cancer cells to evade anti‐tumour immunity, but also show that exosomal PD‐L1 represents an unexplored therapeutic target, which could overcome resistance to current immunotherapies that disrupt PD‐L1/PD‐1 interactions and lead to reactivation of the anti‐tumour immune response.